CAS Number36476-78-5
SynonymsAzetidine-3-carboxylic Acid; 3-Azetidinecarboxylic acid; MFCD00191763; 3-Azetidine carboxylic acid
Molecular FormulaC4H7NO2
Molecular Weight101.10
Purity98%
Density1.3±0.1 g/cm3
Boiling Point242.0±33.0 °C at 760 mmHg
Melting Point286 °C (dec.) (lit.)
AppearanceLight yellow powder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 36476-78-5 |
| Catalog No. | 2A-9004126 |
| Chinese Name | 3-吖丁啶羧酸 |
| Synonyms | Azetidine-3-carboxylic Acid; 3-Azetidinecarboxylic acid; MFCD00191763; 3-Azetidine carboxylic acid |
| Molecular Formula | C4H7NO2 |
| Molecular Weight | 101.10 |
| Purity | 98 |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 242.0±33.0 °C at 760 mmHg |
| Melting Point | 286 °C (dec.) (lit.) |
| Appearance | Light yellow powder |
| Water Solubility | Water solubility: soluble |
| Storage Condition | Sealed, cool, dry and ventilated storage |
| Application | Azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetidine-3-carboxylic acid is also a PROTAC linker based on an alkyl chain and can |
| HTC | 2933990090 |
| PubChem ID | 24864361 |
| MDL Number | MFCD00191763 |
| SMILES | OC(=O)C1CNC1 |
| InChI | 1S/C4H7NO2/c6-4(7)3-1-5-2-3/h3,5H,1-2H2,(H,6,7) |
| InChI Key | GFZWHAAOIVMHOI-UHFFFAOYSA-N |
| NACRES Code | NA.22 |
| UNSPSC | 12352106 |
| Safety Description | S22;S24/25 |
| MSDS | msds/4126_1_36476_78_5.pdf |
| Bioactivity | Azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2 Related Catalog Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Linker Signaling Pathways >> PROTAC >> PROTAC Linker Target Non-cleavable In Vitro ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2]. References [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Boiling Point 242.0±33.0 °C at 760 mmHg Melting Point 286 °C (dec.)(lit.) Molecular Formula C4H7NO2 Molecular Weight 101.104 Flash Point 100.1±25.4 °C Exact Mass 101.047676 PSA 49.33000 LogP -0.86 Vapour Pressure 0.0±1.0 mmHg at 25°C Index of Refraction 1.499 InChIKey GFZWHAAOIVMHOI-UHFFFAOYSA-N SMILES O=C(O)C1CNC1 |
| Use of | Azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2 Properties Name 3-Azetidinecarboxylic Acid Synonym More Synonyms Azetidine-3-carboxylic acid Biological Activity Description Azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2 Related Catalog Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Linker Signaling Pathways >> PROTAC >> PROTAC Linker Non-cleavable In Vitro ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2]. References [1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985. Chemical & Physical Properties Molecular Formula C4H7NO2 Exact Mass 101.047676 PSA 49.33000 LogP -0.86 Index of Refraction 1.499 InChIKey GFZWHAAOIVMHOI-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in Functional Building Blocks | ||
|---|---|---|
| 3-[3,5-Bis(trifluoromethyl)phenyl]prop-2-yn-1-ol | 81613-61-8 | 2A-9003986 |
| 3-Aminobenzaldehyde | 1709-44-0 | 2A-9004103 |
| 3-Aminophenyl trifluoromethyl sulphide | 369-68-6 | 2A-9004110 |
| 3-Aminophenyl trifluoromethyl sulphone | 426-59-5 | 2A-9004111 |
| 3-Aminophenylboronic acid | 30418-59-8 | 2A-9004114 |
| 3-Benzyloxy-4-methoxybenzaldehyde | 6346-05-0 | 2A-9004137 |
| 3-Benzyloxybenzhydrazide | 228419-13-4 | 2A-9004139 |
| 3-Biphenyl-[1,3]dioxol-5-yl-carboxylic acid | 24351-56-2 | 2A-9004148 |
| 3-Bromo-2-(bromomethyl)propionic acid | 41459-42-1 | 2A-9004157 |
| 3-Bromo-2-hydroxy-5-methylbenzaldehyde | 33172-54-2 | 2A-9004169 |
| Browse all Functional Building Blocks products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS